215 related articles for article (PubMed ID: 8537671)
1. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease.
Chan CY; Molrine DC; George S; Tarbell NJ; Mauch P; Diller L; Shamberger RC; Phillips NR; Goorin A; Ambrosino DM
J Infect Dis; 1996 Jan; 173(1):256-8. PubMed ID: 8537671
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease.
Molrine DC; George S; Tarbell N; Mauch P; Diller L; Neuberg D; Shamberger RC; Anderson EL; Phillips NR; Kinsella K; Ambrosino DM
Ann Intern Med; 1995 Dec; 123(11):828-34. PubMed ID: 7486464
[TBL] [Abstract][Full Text] [Related]
3. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.
Sorensen RU; Leiva LE; Giangrosso PA; Butler B; Javier FC; Sacerdote DM; Bradford N; Moore C
Pediatr Infect Dis J; 1998 Aug; 17(8):685-91. PubMed ID: 9726341
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
[TBL] [Abstract][Full Text] [Related]
5. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
[TBL] [Abstract][Full Text] [Related]
6. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.
Giebink GS; Meier JD; Quartey MK; Liebeler CL; Le CT
J Infect Dis; 1996 Jan; 173(1):119-27. PubMed ID: 8537648
[TBL] [Abstract][Full Text] [Related]
8. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children.
Obaro SK; Huo Z; Banya WA; Henderson DC; Monteil MA; Leach A; Greenwood BM
Pediatr Infect Dis J; 1997 Dec; 16(12):1135-40. PubMed ID: 9427458
[TBL] [Abstract][Full Text] [Related]
9. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.
Anttila M; Eskola J; Ahman H; Käyhty H
J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841
[TBL] [Abstract][Full Text] [Related]
10. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media.
Giebink GS; Koskela M; Vella PP; Harris M; Le CT
J Infect Dis; 1993 Feb; 167(2):347-55. PubMed ID: 8421168
[TBL] [Abstract][Full Text] [Related]
12. Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Children's Cancer Study Group Report.
Addiego JE; Ammann AJ; Schiffman G; Baehner R; Higgins G; Hammond D
Lancet; 1980 Aug; 2(8192):450-2. PubMed ID: 6106099
[TBL] [Abstract][Full Text] [Related]
13. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
14. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly.
Sankilampi U; Honkanen PO; Bloigu A; Herva E; Leinonen M
J Infect Dis; 1996 Feb; 173(2):387-93. PubMed ID: 8568300
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
[TBL] [Abstract][Full Text] [Related]
20. Antibody response of patients with Hodgkin's disease to protein and polysaccharide antigens.
Siber GR; Weitzman SA; Aisenberg AC
Rev Infect Dis; 1981; 3 Suppl():S144-59. PubMed ID: 7280445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
